Akkanapally V

No ORCID on file · 2 papers in corpus
2026
Beyond inhibition: harnessing the DRD2-VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer.
Frontiers in oncology ·doi:10.3389/fonc.2026.1818655

Current anti-angiogenic therapies using vascular endothelial growth factor-A/vascular endothelial growth factor receptor-2 (VEGF-A/VEGFR2) inhibitors lack dynamic biomarkers that can facilitate patient selection and optimize dosing; this ca…

review 2026
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities
FASEB journal : official publication of the Federation of American Societies for Experimental Biology ·doi:10.1096/fj.202600843R

Angiogenesis mediated by vascular endothelial growth factor A (VEGF-A) is essential for physiological vascular remodeling but also drives pathological processes, including tumor growth, ocular neovascularization, and inflammation. Emerging …